Cardiol Therapeutics Inc. filings document the formal disclosures of a Canadian life sciences issuer listed on Nasdaq and the TSX. Recent Form 6-K reports furnish press releases and exhibits covering CardiolRx clinical programs, including MAVERIC in recurrent pericarditis and ARCHER in acute myocarditis, as well as CRD-38 development, patent updates, and operating results summarized with audited financial statements and management discussion.
The filing record also documents governance and capital-structure matters, including annual general meeting notices, Class A common share voting mechanics, bought deal private placement terms, underwriting agreements, and warrant indenture provisions. These filings describe the company’s securities, financing arrangements, clinical-development disclosures, and foreign-issuer reporting framework.
Cardiol Therapeutics Inc. (CRDL) reported that it will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, at 10:30 a.m. EDT, with a live webcast available through the Investors section of its website.
The company describes itself as a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, led by its small-molecule drug candidate CardiolRx™, which targets inflammasome pathway activation. Cardiol highlights its MAVERIC Program in recurrent pericarditis, including a completed Phase II MAvERIC-Pilot study and an ongoing pivotal Phase III MAVERIC trial, for which CardiolRx™ has U.S. FDA Orphan Drug Designation. It also notes the completed Phase II ARCHER study in acute myocarditis and ongoing development of CRD-38, a subcutaneous formulation intended for inflammatory heart disease, including heart failure.
MMCAP International Inc. SPC and MM Asset Management Inc. report beneficial ownership of 21,310,099 Class A Common Shares of Cardiol Therapeutics Inc. as of June 30, 2026, representing 17.6% of the class.
The position consists of 15,598,560 shares plus 5,711,539 shares underlying warrants exercisable within 60 days. Both reporting persons have shared voting and dispositive power over all 21,310,099 shares and no sole voting or dispositive power.
Cardiol Therapeutics Inc. reported unaudited interim results for the three and six months ended June 30, 2026. The company remains pre-revenue and recorded a net loss of $6.1 million for the quarter and $16.9 million for the first half of 2026, compared with $8.4 million and $16.6 million in the prior-year periods. Operating expenses for the six months were driven by research and development of $8.1 million and general and administration of $9.5 million, including $4.2 million of share-based compensation.
Cardiol strengthened its balance sheet through a January 2026 unit financing that raised $14.85 million gross and warrant exercises of $2.49 million, increasing cash and cash equivalents to $26.1 million as of June 30, 2026 and total equity to $24.0 million. Management states this cash is expected to fund operations and planned milestones into Q4 2027.
Clinically, Cardiol advanced its lead drug CardiolRx™ in cardiovascular inflammation: the pivotal Phase III MAVERIC trial in recurrent pericarditis reached 75% enrollment, with target enrollment anticipated by the end of Q3 2026, and Phase II ARCHER myocarditis results were published in ESC Heart Failure. The company is also progressing CRD-38, budgeting about $4 million to complete IND-enabling studies by H1 2027.
Cardiol Therapeutics Inc., a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026, at 9:00 a.m. EDT, with a live webcast available via its investor website.
The company highlights its lead small-molecule candidate CardiolRx™, which targets inflammasome pathway activation and is being evaluated in the MAVERIC Program for recurrent pericarditis, including a completed Phase II MAvERIC-Pilot study and an ongoing pivotal Phase III MAVERIC trial, and in the completed Phase II ARCHER study in acute myocarditis. Cardiol also notes U.S. FDA Orphan Drug Designation for CardiolRx in pericarditis and ongoing development of CRD-38, a subcutaneous formulation aimed at inflammatory heart disease, including heart failure.
Cardiol Therapeutics Inc. reported that results from its Phase II MAvERIC study of CardiolRx™ in recurrent pericarditis have been published in the peer‑reviewed Journal of the American Heart Association. The publication appears as the pivotal Phase III MAVERIC trial evaluating CardiolRx™ in recurrent pericarditis nears full patient enrollment.
The Phase II data describe CardiolRx™ being associated with rapid, sustained reductions in pericarditis pain and inflammation, substantial reductions in pericarditis episodes per year, and a favorable safety and tolerability profile, supporting the design of the Phase III trial. Cardiol also highlights its broader pipeline, including the ARCHER program in acute myocarditis and development of CRD‑38 for inflammatory heart disease, with CardiolRx™ holding U.S. FDA Orphan Drug Designation for pericarditis.
Cardiol Therapeutics Inc. reported that it will participate in a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston on July 16, 2026, at 12:20 p.m. Eastern Time. This is an investor-focused conference appearance, not a financial results update.
The company highlights its late-stage development of CardiolRx™, a small-molecule drug targeting inflammasome pathway activation for heart conditions including recurrent pericarditis and acute myocarditis, and its pivotal Phase III MAVERIC trial. Cardiol is also developing CRD-38, a subcutaneous therapy candidate for inflammatory heart disease, including heart failure.
Cardiol Therapeutics Inc. reported the results of its 2026 Annual General Meeting of Shareholders, held virtually on June 24, 2026. Shareholders voted overwhelmingly in favour of all management resolutions.
All eight nominated directors were elected for the ensuing year, each receiving at least 96% of votes cast, and BDO Canada LLP was appointed as auditor for the next fiscal year with authority for directors to set their remuneration.
The filing also reiterates Cardiol’s focus on developing its lead small-molecule drug candidate CardiolRx™ for recurrent pericarditis and acute myocarditis, including a completed Phase II MAvERIC-Pilot study, an ongoing pivotal Phase III MAVERIC trial, and a completed Phase II ARCHER study, as well as its development of CRD-38 for inflammatory heart disease.
Cardiol Therapeutics Inc. is informing investors that its 2026 virtual Annual General Meeting of Shareholders will be webcast on June 24, 2026, at 4:30 p.m. EDT via an online portal, with participation and voting details available through the company’s investor relations website.
The company highlights its focus on anti-inflammatory and anti-fibrotic therapies for heart disease, led by its small-molecule candidate CardiolRx™, which targets inflammasome pathway activation. CardiolRx™ is being evaluated in recurrent pericarditis through the MAVERIC Program, including a completed Phase II pilot study and an ongoing pivotal Phase III trial, and has U.S. FDA Orphan Drug Designation for pericarditis. Cardiol also completed the Phase II ARCHER study in acute myocarditis and is developing CRD-38, a subcutaneous formulation intended for inflammatory heart disease, including heart failure.
Cardiol Therapeutics Inc. is convening an online-only annual general meeting of shareholders on June 24, 2026 at 4:30 p.m. EDT. Shareholders of record on May 7, 2026 can vote on electing eight directors and re‑appointing BDO Canada LLP as auditors.
The company is using notice‑and‑access to provide its circular, 2025 financial statements, and MD&A electronically, with paper copies available on request. The circular details executive and director compensation, including equity awards under Cardiol’s Omnibus Equity Incentive Plan, which allows share-based incentives tied to performance and retention.
Cardiol Therapeutics Inc. ownership update: MMCAP International Inc. SPC and MM Asset Management Inc. report shared beneficial ownership of 21,063,856 Class A Common Shares, representing 17.9% of the class as of March 31, 2026. The statement shows 15,352,317 directly owned shares plus 5,711,539 shares underlying warrants exercisable within 60 days. The filing attributes the Fund as the direct owner and the Adviser as investment manager; each Reporting Person disclaims ownership beyond the shares shown.